DE69435049D1 - Chimäre proteine zur vermeidung der komplementaktivierung - Google Patents

Chimäre proteine zur vermeidung der komplementaktivierung

Info

Publication number
DE69435049D1
DE69435049D1 DE69435049T DE69435049T DE69435049D1 DE 69435049 D1 DE69435049 D1 DE 69435049D1 DE 69435049 T DE69435049 T DE 69435049T DE 69435049 T DE69435049 T DE 69435049T DE 69435049 D1 DE69435049 D1 DE 69435049D1
Authority
DE
Germany
Prior art keywords
chimeric proteins
activation
complemental
avoiding
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69435049T
Other languages
English (en)
Inventor
Jone-Long Ko
Paul J Higgins
C Grace Yeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69435049D1 publication Critical patent/DE69435049D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69435049T 1993-09-24 1994-09-23 Chimäre proteine zur vermeidung der komplementaktivierung Expired - Lifetime DE69435049D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12659693A 1993-09-24 1993-09-24
US08/310,416 US5679546A (en) 1993-09-24 1994-09-22 Chimeric proteins which block complement activation
PCT/US1994/010786 WO1995008570A1 (en) 1993-09-24 1994-09-23 Chimeric proteins which block complement activation

Publications (1)

Publication Number Publication Date
DE69435049D1 true DE69435049D1 (de) 2008-01-24

Family

ID=26824842

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69435049T Expired - Lifetime DE69435049D1 (de) 1993-09-24 1994-09-23 Chimäre proteine zur vermeidung der komplementaktivierung

Country Status (9)

Country Link
US (2) US5679546A (de)
EP (1) EP0723555B1 (de)
JP (2) JP3860605B2 (de)
CN (1) CN1057097C (de)
AT (1) ATE380875T1 (de)
AU (1) AU697167B2 (de)
CA (1) CA2172610A1 (de)
DE (1) DE69435049D1 (de)
WO (1) WO1995008570A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482404B1 (en) 1989-10-12 2002-11-19 David James White Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor
US5866402A (en) * 1995-05-05 1999-02-02 Chiron Corporation Chimeric MCP and DAF proteins with cell surface localizing domain
FR2736916B1 (fr) * 1995-07-21 1997-09-19 Univ Paris Curie Proteines hetero-multimeriques recombinantes du type alpha-beta c4bp
AU1297899A (en) * 1997-10-31 1999-05-24 Walter Reed Army Institute Of Research Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
PT1054693E (pt) * 1998-02-20 2009-01-22 Genentech Inc Inibidores da activação do complemento
US6297024B1 (en) 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
US6235494B1 (en) 1999-02-08 2001-05-22 The Scripps Research Institute Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
JP2003513635A (ja) * 1999-11-01 2003-04-15 カイロン コーポレイション 発現ベクター、トランスフェクション系、およびそれらの使用方法
DK1325033T3 (da) 2000-10-10 2010-04-06 Genentech Inc Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
WO2002100148A2 (en) * 2001-06-08 2002-12-19 Novartis Ag Treatment or prophylaxis of insulin-producing cell graft rejection
JP2005539067A (ja) * 2002-09-16 2005-12-22 エリューシス セラピューティクス，インコーポレーテッド ポリエチレングリコールリンカーを用いる二重特異性分子の産生
ES2392511T3 (es) * 2002-11-15 2012-12-11 Musc Foundation For Research Development Moduladores de complemento dianas sobre el receptor 2 de complemento
WO2005069726A2 (en) 2004-01-21 2005-08-04 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
PT1713503E (pt) * 2004-02-10 2013-11-14 Nat Jewish Health Inibição do factor b, a via alternativa do complemento e métodos relacionados
ATE500836T1 (de) * 2004-03-31 2011-03-15 The Feinstein Inst Medical Res Adrenomedullin und adrenomedullin-bindungsprotein zur ischämie/reperfusionsbehandlung
US8703693B2 (en) * 2004-03-31 2014-04-22 The Feinstein Institute For Medical Research Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
CN101227924A (zh) * 2005-05-26 2008-07-23 科罗拉多大学评议会 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制
JP2009514888A (ja) * 2005-11-04 2009-04-09 ジェネンテック・インコーポレーテッド 眼疾患を処置するための補体経路の阻害剤の使用
CA2656063C (en) 2006-06-21 2016-10-18 Musc Foundation For Research Development Targeting complement factor h for treatment of diseases
TW201534620A (zh) * 2006-11-02 2015-09-16 Genentech Inc 人類化之抗-因子ｄ抗體及其用途
EP2134173A4 (de) * 2007-03-01 2010-11-10 Wellstat Ophthalmics Corp Behandlung von erkrankungen, die durch entzündung gekennzeichnet sind
CN101668773B (zh) * 2007-03-14 2016-08-31 亚力史制药公司 人工程化抗b因子抗体
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US20090324585A1 (en) * 2008-06-12 2009-12-31 The Trustees of the Leland Standford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
CA2795311A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
CN102234332B (zh) * 2010-04-26 2014-12-17 浙江海正药业股份有限公司 一种重组人血白蛋白及其融合蛋白的分离纯化工艺
KR20130080443A (ko) 2010-05-14 2013-07-12 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 개선된 보체 수용체 ２(ｃｒ２) 표적 그룹들
WO2011163412A1 (en) 2010-06-22 2011-12-29 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the c3d fragment of complement component 3
NZ608814A (en) 2010-09-03 2015-06-26 Stem Centrx Inc Novel modulators and methods of use
CA2840270C (en) 2011-06-22 2023-09-26 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
US9243070B2 (en) 2012-04-03 2016-01-26 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor Bb antibodies and uses thereof
EP2855529A4 (de) 2012-05-24 2015-12-09 Alexion Pharma Inc Humanisierte anti-faktor-b-antikörper
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
EA201690213A1 (ru) 2013-08-12 2016-07-29 Дженентек, Инк. Композиции и способ лечения связанных с комплементом состояний
RU2673036C2 (ru) 2014-02-27 2018-11-21 Аллерган, Инк. АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb
AU2015253042A1 (en) 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
EP3633371A1 (de) 2014-12-18 2020-04-08 F. Hoffmann-La Roche AG Assay und verfahren zur bestimmung cdc-entlockender antikörper
AU2016326627B2 (en) * 2015-09-24 2022-12-15 The Trustees Of The University Of Pennsylvania Composition and method for treating complement-mediated disease
EP3368074A2 (de) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-faktor-d-antikörper und -konjugate
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
LT3394089T (lt) * 2015-12-23 2021-11-25 eleva GmbH Polipeptidai, skirti komplemento aktyvacijos inhibicijai
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
WO2020213004A1 (en) * 2019-04-13 2020-10-22 National Centre For Cell Science Daf-mcp chimeric proteins, process to manufacture the same and use of the chimeric protein for treating pathological conditions involving the complement system

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) * 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
US4774180A (en) * 1986-02-26 1988-09-27 Massachusetts Institute Of Technology Construction and application of polyproteins
US5264357A (en) * 1985-05-24 1993-11-23 Genentech, Inc. Nucleic acids vectors and cells for the synthesis of membrane anchor fusion polypeptides
IL82390A0 (en) * 1986-05-02 1987-10-30 Genentech Inc Nucleic acid and methods for the synthesis of novel daf compositions
DK0489116T3 (da) * 1989-08-22 1994-05-02 Immunex Corp Fusionsproteiner omfattende GM-CSF og IL-3
WO1991011461A1 (en) * 1990-01-26 1991-08-08 Biogen, Inc. C4 binding protein fusion proteins
EP0512733A2 (de) * 1991-05-03 1992-11-11 Washington University Modifizierter Komplementsystemregler
US5252216A (en) * 1992-03-24 1993-10-12 Smithkline Beecham Corporation Protein purification
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins

Also Published As

Publication number Publication date
CA2172610A1 (en) 1995-03-30
CN1057097C (zh) 2000-10-04
JP3860605B2 (ja) 2006-12-20
JP2005041882A (ja) 2005-02-17
ATE380875T1 (de) 2007-12-15
EP0723555B1 (de) 2007-12-12
JPH09502985A (ja) 1997-03-25
US5679546A (en) 1997-10-21
CN1138863A (zh) 1996-12-25
EP0723555A4 (de) 1999-04-28
US5851528A (en) 1998-12-22
AU8071994A (en) 1995-04-10
AU697167B2 (en) 1998-10-01
WO1995008570A1 (en) 1995-03-30
EP0723555A1 (de) 1996-07-31

Similar Documents

Publication Publication Date Title
DE69435049D1 (de) Chimäre proteine zur vermeidung der komplementaktivierung
ATE226634T1 (de) Fibronektin bindendes protein
NO971875L (no) Cathepsin 02 protease
BG104149A (en) Interleukin-18-binding proteins, methods for their preparation and administration
ATE389023T1 (de) Kontrolle der schotendehiszenz
HK51197A (en) Platelet blocking peptides
DE69837475D1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
DE69634077D1 (de) Haemophilus adhäsionsproteinen
FI930626A0 (fi) Proteinstruktur hos vaexttoxingelonin
ES2185628T3 (es) Procedimiento para preparar proteinas modificadas.
ES2052513T3 (es) Nuevos polipeptidos, su fabricacion y empleo.
FI946076A (fi) Modifioituja Kluyveromyces-hiivoja, valmistus ja käyttö
AU669149B2 (en) Expression signal-peptide-free staphylokinases
ATE256747T1 (de) Glykosyltransferase expression in aspergillus
ATE193324T1 (de) Rekombinante herstellung von laktoperoxidase
SE9604439D0 (sv) New receptor
DK0858465T3 (da) Protein med antitumorvirkning.
MX9701904A (es) Proteinas de enlace de pka novedosas y usos de las mismas.
ATE76081T1 (de) Verfahren zur herstellung von dipeptiden mit nterminalen nichtproteinogenen aminosaeuren.
DE3688974D1 (de) Expressionssysteme zur überproduktion gewünschter proteine.

Legal Events

Date Code Title Description
8332 No legal effect for de